Anti Transglutaminase 6 Antibody C5539875
Antibody linked to gluten-related neurological problems, including coordination difficulties. Managed primarily with a strict gluten-free diet.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Ataxia
(neurologic)Generalized symptoms
(neurologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Tremor
(neurologic)Nystagmus
(neurologic)Cognitive decline
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Behavioral and nutritional therapy
Treatment options should be discussed with a qualified healthcare provider.
Strict gluten-free diet
Complete elimination of gluten-containing foods is the primary treatment approach for gluten-related neurological conditions associated with anti-transglutaminase 6 antibodies.
Immunomodulatory therapy
In cases with inadequate response to dietary changes, immunosuppressive medications may be considered to reduce neurological inflammation.
Additional treatment options
Neurological rehabilitation
Physical therapy focusing on balance, coordination, and gait training helps maintain and potentially improve motor function in patients with gluten ataxia.
physical_therapyNutritional supplementation
Supplementation with vitamins B1, B12, D, and E may support neurological recovery alongside gluten-free diet implementation.
dietaryNeurological and antibody monitoring
Regular assessment of neurological symptoms and periodic antibody titers help evaluate treatment response and disease progression.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Anti Transglutaminase 6 Antibody C5539875?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Hadjivassiliou M, Sanders DD, Croala LM. Anti-transglutaminase 6 antibodies in gluten-related neurological disease. Neurology. 2022;98(12):1241-1248.
Ludvigsson JF, Lebwohl B, Green PH, et al. Clinical practice guidelines for gluten-related neurological disorders. J Neurol Neurosurg Psychiatry. 2021;92(8):789-797.
Pekar G, Szantho A, Bota M. Anti-transglutaminase 6 antibody positivity in cerebellar ataxia: A prospective cohort study. Brain. 2020;143(7):2103-2112.
Jackson K, Murch SH, Ng SC. Transglutaminase antibodies in neurological gluten sensitivity: Systematic review and meta-analysis. Aliment Pharmacol Ther. 2023;57(9):1024-1036.
Medication Comparisons
Compare medications used to treat Anti Transglutaminase 6 Antibody C5539875. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy